公开(公告)号：US20240343752A1

公开(公告)日：2024-10-17

申请号：US18417409

申请日：2024-01-19

申请人： UNIVERSITÄT BERN

发明人： Christian Leumann ,  Damien Evequoz

IPC分类号： C07H19/048 ,  C07D405/04 ,  C07D473/18 ,  C07D473/34 ,  C07F7/18 ,  C07F9/6558 ,  C07F9/6561 ,  C07H19/16 ,  C07H21/00 ,  C12N15/113

CPC分类号： C07H19/048 ,  C07D405/04 ,  C07D473/18 ,  C07D473/34 ,  C07F7/1804 ,  C07F9/65586 ,  C07F9/65616 ,  C07H19/16 ,  C07H21/00 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2320/33

摘要： Oligomers prepared from a bicyclic nucleoside having the formula (I) shown below:




in which each of T1 and T2 is independently OR1 or OR2; R1 is H or a hydroxyl protecting group, R2 is a phosphorus moiety; and Bx is a nucleobase. The compounds, bicyclic nucleosides and oligomers are useful for the prevention, treatment or diagnosis of muscular dystrophy.

公开(公告)号：US20240109932A1

公开(公告)日：2024-04-04

申请号：US18517380

申请日：2023-11-22

申请人： Metro International Biotech, LLC

发明人： Jonathan N. Kremsky ,  Bruce Szczepankiewicz ,  Karsten Koppetsch ,  Joseph Harris ,  Mateusz Pitak ,  Martin Bates

IPC分类号： C07H19/048 ,  C30B7/00 ,  C30B29/54

CPC分类号： C07H19/048 ,  C30B7/00 ,  C30B29/54 ,  C07B2200/13

摘要： The present disclosure relates to crystalline solids comprising a compound of Formula (I),




wherein R is n-propyl, and methods of making compounds of Formula (I) wherein R is C1-C4 alkyl or C2-C4 alkenyl. The present disclosure also relates to crystalline solids comprising a compound of Formula (II),




The present disclosure further relates to methods of preparing the crystalline solids, and pharmaceutical preparations of the crystalline solids, and use of such pharmaceutical preparations in treatment of diseases and conditions.

公开(公告)号：US20240010668A1

公开(公告)日：2024-01-11

申请号：US18233265

申请日：2023-08-11

申请人： Roche Sequencing Solutions, Inc.

发明人： Frank Bergmann ,  Peter Crisalli ,  Dieter Heindl ,  Omid Khakshoor ,  Meng Taing

IPC分类号： C07H19/06 ,  C07H19/048

CPC分类号： C07H19/06 ,  C07H19/048

摘要： The present disclosure provides 3′ protected nucleotides, including those 3′ protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3′ protected nucleotides are also disclosed, such as the sequencing of a nucleic acid using a nanopore or the sequencing of a nucleic acid via sequencing-by-synthesis.

公开(公告)号：US20230348520A1

公开(公告)日：2023-11-02

申请号：US17907346

申请日：2021-02-10

申请人： ORIENTAL YEAST CO., LTD.

发明人： Yukiko TAKETANI ,  Hirokazu MATSUKAWA ,  Yoshiko SUNAHARA

IPC分类号： C07H19/048 ,  C12Q1/32 ,  B01D15/08

CPC分类号： C07H19/048 ,  C12Q1/32 ,  B01D15/08 ,  C12Y101/01027

摘要： A compound includes β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof. A purity of the compound as measured through HPLC is 95% or higher. A reactivity of the compound with lactate dehydrogenase is 30 units or higher.

公开(公告)号：US20230295211A1

公开(公告)日：2023-09-21

申请号：US18184456

申请日：2023-03-15

申请人： ChromaDex Inc.

发明人： Aron Erickson ,  Philip Redpath ,  Jacob Roodman ,  Richard Nygaard

IPC分类号： C07H19/048

CPC分类号： C07H19/048 ,  C07B2200/13

摘要： This disclosure relates to a process for producing Crystalline Beta Nicotinamide Riboside Triacetate Chloride with improved physical property characteristics. A substantially crystalline Beta Nicotinamide Riboside Triacetate Chloride, or a salt, or a solvate thereof is described having a chemical purity of greater than about 90% (w/w) and containing less than about 5000 ppm ethanol.

公开(公告)号：US20230271995A1

公开(公告)日：2023-08-31

申请号：US18245044

申请日：2021-09-14

申请人： SOCIETE DES PRODUITS NESTLE S.A. ,  CORNELL UNIVERSITY

发明人： AMIN ZAREI ,  LEILA KHAZDOOZ ,  MOJTABA ENAYATINOOK ,  SARA MADARSHAHIAN ,  ALIREZA ABBASPOURRAD ,  GERHARD UFHEIL

IPC分类号： C07H19/048

CPC分类号： C07H19/048

摘要： A method of producing 1,4-dihydronicotinamide riboside (NRH) is disclosed. The method comprises providing nicotinamide riboside chloride (NRCl) in a liquid solution; adding a metal dithionite into the liquid solution under a first temperature; and reacting the metal dithionite with the nicotinamide riboside chloride (NRCl) in the liquid solution under a second temperature to form a mixture, wherein at least a portion of the mixture comprises the 1,4-dihydronicotinamide riboside (NRH).

公开(公告)号：US20230234981A1

公开(公告)日：2023-07-27

申请号：US18191901

申请日：2023-03-29

申请人： Jumpstart Fertility Pty Ltd ,  Life Biosciences Inc.

发明人： Michel Wathier ,  Roland Dolle ,  Sebastian Mario Marcuccio ,  Rohan David Joyce ,  Simon Tucker

IPC分类号： C07H19/048 ,  A61P15/08

CPC分类号： C07H19/048 ,  A61P15/08

摘要： The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+:




wherein A, M1, M2, k, R1, R2, and R3 are as described herein.

公开(公告)号：US20220324899A1

公开(公告)日：2022-10-13

申请号：US17633693

申请日：2020-08-13

申请人： Metro International Biotech, LLC

发明人： Matthew Baevsky ,  Karen Lavery ,  Jonathan N. Kremsky ,  James M. McKearin

IPC分类号： C07H19/048 ,  A61P35/00 ,  A61K31/706 ,  A61P1/16

摘要： The invention relates to compounds and compositions for modulation of nicotinamide adenine dinucleotide (NAD+). The invention also relates to methods of making such compounds and compositions. The invention relates to pharmaceutical compositions containing one or more NAD+ modulating compounds as a first ingredient in combination with one or more active pharmaceutical ingredients. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and/or improving cell and tissue survival.

公开(公告)号：US11447514B2

公开(公告)日：2022-09-20

申请号：US17055101

申请日：2019-05-17

申请人： Roche Diagnostics Operations, Inc.

发明人： Urs Spitz ,  Günter Schabert ,  Aysel Soydemir ,  Lukas Wick

IPC分类号： C07H1/06 ,  C07H19/048

摘要： The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supplements. Furthermore, the present invention relates to a composition comprising amorphous (thio)nicotinamide ribofuranoside salts and its use as nutritional (dietary) supplement.

公开(公告)号：US20220259250A1

公开(公告)日：2022-08-18

申请号：US17736834

申请日：2022-05-04

申请人： The Queen's University of Belfast

发明人： Marie Migaud ,  Philip Redpath ,  Kerri Crossey ,  Mark Doherty

IPC分类号： C07H19/048 ,  C07H1/00 ,  C07H1/06

摘要： Methods of preparing nicotinamide riboside and derivatives thereof, are described. In an aspect, the invention relates to a method of making a compound of formula (II), or a salt, or solvate thereof: wherein n is 0 or 1; Y is O or S; m is 1; R1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted primary or secondary amino, and substituted or unsubstituted azido; and R2-R5 are each H.